PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Division of Infectious Diseases, Brigham and Women\'s Hospital, 75 Francis Street, Boston, MA 02115, USA; Harvard Medical School, Boston, MA 02115, USA. Electronic address: acsherman@bwh.harvard.edu.\', \'Division of Infectious Diseases, Brigham and Women\'s Hospital, 75 Francis Street, Boston, MA 02115, USA; Harvard Medical School, Boston, MA 02115, USA; Division of Infectious Diseases, Centre Hospitalier de l\'Université de Montréal, 1000 Rue Saint-Denis, Bureau F06.1102b, Montreal, Quebec H2X 0C1, Canada.\', \'Division of Infectious Diseases, Brigham and Women\'s Hospital, 75 Francis Street, Boston, MA 02115, USA; Harvard Medical School, Boston, MA 02115, USA.\']
?:citedBy
  • -1
?:creator
?:doi
  • S0272-2712(21)00088-310.1016/j.cll.2021.10.008
?:doi
?:hasPublicationType
?:journal
  • Clinics in laboratory medicine
is ?:pmid of
?:pmid
?:pmid
  • 35153045
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 0.839
?:rankingScore_hIndex
  • 47
is ?:relation_isRelatedTo_publication of
?:title
  • Vaccine-Induced Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Response and the Path to Accelerating Development (Determining a Correlate of Protection).
?:type
?:year
  • 2022

Metadata

Anon_0  
expand all